ArticleSexual medicine2025
Causal effects and plasma protein mediators between type 2 diabetes and erectile dysfunction: a Mendelian randomization study.
Article in Sexual medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The effect of type 2 diabetes genetic predisposition on non-cardiovascular comorbidities.Nature communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The linkage between type 2 diabetes (T2DM) and erectile dysfunction (ED) is not yet fully understood. Aim: This study aims to evaluate the causal influence of T2DM on ED and to determine whether plasma proteins mediate this relationship using Mendelian randomization (MR). Methods: We extracted data on T2DM and plasma proteins from multiple genome-wide association study databases, encompassing European and East Asian populations. The ED dataset comprised 223 805 individuals of European descent. A 2-sample MR analysis was conducted using inverse-variance weighted (IVW), MR-Egger, weighted median, and weighted mode methodologies. Additionally, mediation and sensitivity analyses were performed to assess the robustness of the findings and the mediating role of plasma proteins. Outcomes: The MR analysis revealed a significant increase in ED incidence associated with T2DM (IVW-fixed odds ratio [OR] = 1.091, 95% confidence intervals [CI]: 1.084-1.098), with sensitivity checks confirming no pleiotropic outliers. Results: We identified 127 plasma proteins linked to ED, of which 15 were influenced by T2DM. The mediation MR analysis indicated 9 plasma proteins with consistent mediation effects: SERPINA10, MATN4, NAB1, NUCB1, SLAMF6, and ANG were associated with negative effects, while NCAM1, CTSB, and WFIKKN2 demonstrated protective effects. Clinical translation: These findings suggest that T2DM has a direct causal effect on ED, with several plasma proteins serving as potential mediators, highlighting the importance of targeting these proteins for future therapeutic interventions in ED among T2DM patients. Strengths and limitations: This study leverages a comprehensive MR approach and a large sample size, though it is limited by the observational nature of genetic associations and the necessity for further clinical validation. Conclusion: The study enhances our understanding of the biological mechanisms linking T2DM and ED, highlighting plasma proteins as potential mediators and targets for therapeutic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.